Literature DB >> 19932908

Hepatocellular carcinoma associated lipid metabolism reprogramming.

Nicholas James Skill1, Rachael E Scott, Jianmin Wu, Mary A Maluccio.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is a primary malignancy of the liver with a high worldwide prevalence and poor prognosis. Previous data, by Affymetrix microarray analysis, has shown a decrease in genes involved in phospholipid catabolism, fatty acid catabolism, choline metabolism, and bile acid metabolism in HCC compared with control tissue. The aim of this study was to better understand metabolic processes in relation to the development of HCC.
MATERIALS AND METHODS: Tumor, plasma, and bile samples were collected at the time of hepatic resection for HCC. All bile specimens were collected from the gallbladder at the beginning of the case. Normal bile and plasma were collected from patients undergoing cholecystectomy for non-neoplastic disease. Liver biopsy samples were taken from both tumor and adjacent normal tissue. Phospholipid levels were evaluated by enzyme-linked immunosorbent assay (ELISA) and high performance thin layer chromatography (HPTLC).
RESULTS: Targeted phospholipid analysis by HPTLC and ELISA showed a modified choline metabolic profile within the liver, bile, and serum, culminating in an increased synthesis of lysophosphatidic acid (LPA). Choline was significantly increased in tumor tissue; lysophosphatidylcholine (LPC) was increased within bile while LPA was increased in all three biological samples of HCC patients compared with controls. Phosphatidylcholine was not significantly changed.
CONCLUSIONS: HCC is congruent with a reprogramming of choline catabolism and phospholipid metabolism. Increased LPA may provide a potent mitogenic and proliferative microenvironment via autocrine/paracrine activation of high-affinity G-protein-coupled receptors. Additional research is required to better understand the role of these pathways in HCC development.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19932908     DOI: 10.1016/j.jss.2009.09.005

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  16 in total

1.  Altered lysophosphatidic acid (LPA) receptor expression during hepatic regeneration in a mouse model of partial hepatectomy.

Authors:  Kerri A Simo; David J Niemeyer; Erin M Hanna; Jacob H Swet; Kyle J Thompson; David Sindram; David A Iannitti; Ashley L Eheim; Eugene Sokolov; Valentina Zuckerman; Iain H McKillop
Journal:  HPB (Oxford)       Date:  2013-09-24       Impact factor: 3.647

2.  Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification.

Authors:  Diren Beyoğlu; Sandrine Imbeaud; Olivier Maurhofer; Paulette Bioulac-Sage; Jessica Zucman-Rossi; Jean-François Dufour; Jeffrey R Idle
Journal:  Hepatology       Date:  2013-05-08       Impact factor: 17.425

3.  Gadoxetate acid-enhanced MRI of hepatocellular carcinoma in a c-myc/TGFα transgenic mouse model including signal intensity and fat content: initial experience.

Authors:  Huedayi Korkusuz; Lea Knau; Wolfgang Kromen; Frank Huebner; Renate Hammerstingl; Sebastian Lindemayr; Verena Bihrer; Albrecht Piiper; Thomas J Vogl
Journal:  Cancer Imaging       Date:  2012-03-07       Impact factor: 3.909

Review 4.  Functional imaging techniques in hepatocellular carcinoma.

Authors:  V Goh; D Sarker; S Osmany; G J R Cook
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-21       Impact factor: 10.057

5.  Evaluation of 11C-acetate and 18F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma.

Authors:  Paul R Territo; Mary Maluccio; Amanda A Riley; Brian P McCarthy; James Fletcher; Mark Tann; Romil Saxena; Nicholas J Skill
Journal:  BMC Med Imaging       Date:  2015-05-16       Impact factor: 1.930

6.  Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis.

Authors:  Jiguang Ma; Wanxing Duan; Suxia Han; Jianjun Lei; Qinhong Xu; Xin Chen; Zhengdong Jiang; Ligang Nan; Jiahui Li; Ke Chen; Liang Han; Zheng Wang; Xuqi Li; Erxi Wu; Xiongwei Huo
Journal:  Oncotarget       Date:  2015-08-28

7.  Expression and function of lysophosphatidic acid receptors (LPARs) 1 and 3 in human hepatic cancer progenitor cells.

Authors:  Valentina Zuckerman; Eugene Sokolov; Jacob H Swet; William A Ahrens; Victor Showlater; David A Iannitti; Iain H Mckillop
Journal:  Oncotarget       Date:  2016-01-19

8.  Potential diagnostic and prognostic marker dimethylglycine dehydrogenase (DMGDH) suppresses hepatocellular carcinoma metastasis in vitro and in vivo.

Authors:  Gang Liu; Guojun Hou; Liang Li; Yixue Li; Weiping Zhou; Lei Liu
Journal:  Oncotarget       Date:  2016-05-31

9.  Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma.

Authors:  Oleg V Grinchuk; Surya P Yenamandra; Ramakrishnan Iyer; Malay Singh; Hwee Kuan Lee; Kiat Hon Lim; Pierce Kah-Hoe Chow; Vladamir A Kuznetsov
Journal:  Mol Oncol       Date:  2017-12-12       Impact factor: 6.603

10.  EDG2 enhanced the progression of hepatocellular carcinoma by LPA/PI3K/AKT/ mTOR signaling.

Authors:  Meng Xu; Zhikui Liu; Cong Wang; Bowen Yao; Xin Zheng
Journal:  Oncotarget       Date:  2017-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.